I agree the deal will be complex. It will be for Trofentide and...

I agree the deal will be complex. It will be for Trofentide and Retts only, but I would be sure who ever they are dealing with will want last rights on any future indications or molecules. This deal will include the long term play where Neuren can extract maximum value for assets but roll them out through the same partner. I can possibly imagine a future where Biogen has trof for Rett and Eli has trof for Fragile-X and Merck has 2591. Not to mention the primary partner will already have all the manufacturing infrastructure in mass production.

I think the deal will be all encompassing from a rights perspective, with only commercials on Trof for Rett. Further commercials will be negotiated as indications and molecules hit suitable milestones.